Tabercarpamine I






Names

    • Tabercarpamine I

Attributes

  • Canonical SMILES

    CC([H])([H])[C@]1([H])C(NCC2)[C@]3(C(OC)=O)C4=C2C5=CC=C(OC)C=C5N4C(C(C1)C3)=O

  • InChI

    InChI=1S/C22H26N2O4/c1-4-12-9-13-11-22(21(26)28-3)18(12)23-8-7-16-15-6-5-14(27-2)10-17(15)24(19(16)22)20(13)25/h5-6,10,12-13,18,23H,4,7-9,11H2,1-3H3/t12-,13?,18?,22-/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 69.56
  • #RotBonds: 3
  • MW: 382.4600000000002
  • HBD: 1
  • HBA: 6
  • logP: 2.665000000000001
  • Chemical Formula: C22H26N2O4


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. corymbosa Malaysia, China 1679252 GK604

External Databases


References

  • Tabercarpamines A-J, apoptosis-inducing indole alkaloids from the leaves of Tabernaemontana corymbosa. J Nat Prod, 2014 (PMID 24773071).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Growth inhibitory

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -4.82
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -4.66
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability -2.34
    Distribution Blood-Brain Barrier (Central Nervous System) -2.67
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 0.72
    Plasma Protein Binding 42.86
    Steady State Volume of Distribution 2.3
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 10.18
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor 1.33
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.59
    Liver Injury II Toxic
    hERG Blockers Safe
    Daphnia Maga 10.09
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -22.32
    Rat (Acute) 3.14
    Rat (Chronic Oral) 1.69
    Fathead Minnow 4.28
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 442.23
    Hydration Free Energy -6.07
    Log(D) at pH=7.4 2.71
    Log(P) 1.87
    Log S -2.98
    Log(Vapor Pressure) -8.33
    Melting Point 192.09
    pKa Acid 9.87
    pKa Basic 6.75